This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waites, K. B.
Right arrow Articles by Dowzicky, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waites, K. B.
Right arrow Articles by Dowzicky, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2006, p. 3479-3484, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00210-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Antimicrobial Susceptibility among Pathogens Collected from Hospitalized Patients in the United States and In Vitro Activity of Tigecycline, a New Glycylcycline Antimicrobial

Ken B. Waites,1* Lynn B. Duffy,1 and Michael J. Dowzicky2

University of Alabama at Birmingham, Birmingham, Alabama,1 Wyeth Pharmaceuticals, Collegeville, Pennsylvania2

Received 17 February 2006/ Returned for modification 15 May 2006/ Accepted 23 July 2006

The activities of tigecycline and comparators against isolates collected from 76 U.S. centers between January 2004 and September 2005 were assessed. Tigecycline MIC90s were ≤2 µg/ml for Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus agalactiae.

* Corresponding author. Mailing address: Section of Clinical Microbiology, University of Alabama at Birmingham, 619 South 19th Street, Birmingham, AL 35249. Phone: (205) 934-4960. Fax: (205) 975-4468. E-mail: waites{at}path.uab.edu.

Antimicrobial Agents and Chemotherapy, October 2006, p. 3479-3484, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00210-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zhanel, G. G., Baudry, P. J., Tailor, F., Cox, L., Hoban, D. J., Karlowsky, J. A. (2009). Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother 64: 824-828 [Abstract] [Full Text]  
  • Baughman, R. P. (2009). The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24: 230-241 [Abstract]  
  • Crandon, J. L., Banevicius, M. A., Nicolau, D. P. (2009). Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model. Antimicrob. Agents Chemother. 53: 1165-1169 [Abstract] [Full Text]  
  • Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895-904 [Abstract] [Full Text]  
  • Wiskur, B. J., Hunt, J. J., Callegan, M. C. (2008). Hypermucoviscosity as a Virulence Factor in Experimental Klebsiella pneumoniae Endophthalmitis. IOVS 49: 4931-4938 [Abstract] [Full Text]  
  • Pillar, C. M., Draghi, D. C., Dowzicky, M. J., Sahm, D. F. (2008). In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest. J. Clin. Microbiol. 46: 2862-2867 [Abstract] [Full Text]  
  • Vasilev, K., Reshedko, G., Orasan, R., Sanchez, M., Teras, J., Babinchak, T., Dukart, G., Cooper, A., Dartois, N., Gandjini, H., Orrico, R., Ellis-Grosse, E., on behalf of the 309 Study Group, (2008). A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62: i29-i40 [Abstract] [Full Text]  
  • Valentine, S. C., Contreras, D., Tan, S., Real, L. J., Chu, S., Xu, H. H. (2008). Phenotypic and Molecular Characterization of Acinetobacter baumannii Clinical Isolates from Nosocomial Outbreaks in Los Angeles County, California. J. Clin. Microbiol. 46: 2499-2507 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Werner, G., Gfrorer, S., Fleige, C., Witte, W., Klare, I. (2008). Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 61: 1182-1183 [Full Text]  
  • Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., Bonomo, R. A. (2007). Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 3471-3484 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»